Britain's Scale-Up Problem: Why Its Best Companies Keep Choosing New York Over London

The UK builds world-class startups better than almost anywhere else. It just can't seem to hold onto them once they succeed.

Ask most people to name a British startup success story, and they'll probably manage it without much trouble: ARM, Wise, Deliveroo, Revolut. Ask them where those companies' shares actually trade today, or where their next funding round is likely to come from, and the answer gets a lot less flattering to London. That gap, between Britain's genuine talent for creating companies and its increasingly shaky ability to keep them, has quietly become one of the more consequential economic stories of 2026. It's not an abstract policy debate confined to Financial Times op-eds. Over the first eight months of this year alone, three household names in UK business, CRH, Flutter Entertainment, and Smurfit Westrock, have formally delisted from the London Stock Exchange, each one choosing to consolidate its shares exclusively on the New York Stock Exchange instead. None of these were struggling companies looking for a lifeline. All three were profitable, established businesses making a calculated bet that London simply couldn't offer them what New York could. A pattern, not a one-off To understand why this matters beyond three corporate press releases, it helps to zoom out. In 2024 alone, 88 companies either delisted from the London Stock Exchange entirely or shifted their primary listing elsewhere, according to market data widely cited by analysts tracking the exchange's health. That same year, London slipped to twentieth place in global IPO rankings, managing just 18 new listings, a startling comedown for an exchange that spent decades as one of the world's two or three most important financial centers. The list of departures reads like a roll call of genuinely significant British and British-adjacent businesses: Wise, ARM, TUI, Ashtead, Indivior, Just Eat Takeaway, Petershill Partners, Marsh & McLennan's various UK operations, and now, in 2026, CRH, Flutter, and Smurfit Westrock. AstraZeneca, while retaining its London listing for now, moved to a direct NYSE listing in February 2026 specifically to give itself the flexibility to lean further into the US market over time, a move widely read as a hedge against exactly the kind of full departure its peers have already made.

The companies that left in 2026, and why

Each of this year's departures has its own specific rationale, but the underlying logic rhymes across all three. CRH, the building materials giant, shifted its primary listing to New York back in September 2023 and spent two and a half years watching its London trading volumes dwindle before finally announcing a complete delisting in April 2026, alongside a plan to cancel its remaining preference shares. The company was blunt about the reasoning: maintaining a London listing had become an ongoing cost and regulatory burden with diminishing practical benefit, given how little actual trading activity remained there.

Flutter Entertainment, the FanDuel owner and one of the largest names in global sports betting, followed a similar arc, having shifted its primary listing to New York in May 2024 before announcing in June 2026 that it would delist from London entirely, effective August 3. Smurfit Westrock, the packaging giant formed through a major transatlantic merger, delisted from London in June 2026 for effectively the same reason: since its own primary listing shifted to New York in July 2024, the overwhelming majority of trading activity had already migrated there, making a dual listing an expensive formality rather than a genuine source of liquidity.

Why New York keeps winning the argument

It would be easy to read this pattern as a story about disloyal executives chasing prestige, but the reality is far more mechanical and far less sentimental than that framing suggests. The core issue is a persistent valuation discount: companies listed in London routinely trade at meaningfully lower multiples than near-identical peers listed on American exchanges, which means the exact same business, with the exact same revenue and growth prospects, can simply be worth more on paper by virtue of which exchange its shares sit on.

For a founder, board, or major shareholder, that gap isn't a rounding error, it can represent hundreds of millions or even billions of dollars in market capitalization, which makes the decision to move listings feel less like a judgment call and more like a fiduciary obligation. The structural roots of that discount run deep: differences in how domestic pension funds allocate capital, the mechanics of global index fund construction, and the simple, brute fact that American equity markets are dramatically larger and more liquid than their UK counterpart, meaning shares can be bought and sold in bigger volumes without moving the price as much.

"A listing venue is a financing choice, and the underlying business usually continues exactly as it did before. The venue changed. The company didn't."

It's not just about listings, it's about funding earlier

The exodus of established companies to New York is really just the most visible symptom of a much earlier problem: British companies routinely struggle to raise the growth-stage capital they need long before an IPO ever becomes relevant. According to British Business Bank data, UK venture capital investment ran roughly 32% lower than the United States between 2023 and 2025 once adjusted for the relative size of each economy, a gap that widens considerably at the later funding stages where companies need the most capital to compete globally.

The numbers get more specific, and more uncomfortable, the closer you look. Equity investment into UK smaller businesses fell 4% to £12.3 billion in 2025, with early-stage seed deals down 27% and venture-stage deals down 13% year-on-year. Investors have also concentrated their capital into fewer, larger transactions, with the top ten fundraisings of 2025 accounting for nearly a quarter of all UK investment, the highest concentration level since 2020, a trend that leaves a thinner pipeline of mid-sized companies working their way up through the funding stages that eventually produce IPO-ready businesses.

Where the UK still genuinely excels

It's worth being fair to Britain's strengths here. UK university spinout companies saw venture capital deal volumes rise 95% between 2021 and 2025 compared to the previous five-year period, outpacing the US, Germany, and France over the same window. The UK remains the third-largest venture capital market globally, having overtaken India. The problem genuinely sits at the scale-up stage, not at the starting line.

What Britain is actually doing about it

To its credit, the response from UK policymakers and institutions hasn't been purely rhetorical. The Financial Conduct Authority's new UK Listing Rules, in force since July 2024, replaced the old premium and standard listing segments with a simplified, single category for commercial companies and relaxed several eligibility requirements that had previously made London a comparatively cumbersome place to go public. A new prospectus regime that took effect in January 2026 has made secondary fundraising for already-listed companies noticeably faster and cheaper, and newly listed firms now receive a three-year exemption from stamp duty reserve tax, removing a cost that previously nudged some listings toward other markets.

On the capital side, the British Business Bank has dramatically ramped up its direct investment activity, more than doubling its equity investments from £290 million in October 2025 to over £600 million by mid-2026, spread across more than 50 high-growth UK scale-ups in sectors including life sciences, deep tech, AI, and fintech. The Bank has set a target of deploying roughly £400 million annually into direct equity deals as part of a broader £2 billion yearly commitment to the UK venture capital ecosystem, alongside a newly announced British Growth Partnership designed specifically to pull more domestic pension fund capital into high-growth British companies, an effort to fix the structural allocation issue at its actual source rather than simply subsidizing individual deals.

After several years of unrelenting bad headlines, there are genuine, if still tentative, signs that London's IPO market may be stabilizing. According to analysis from EY-Parthenon, London recorded seven IPOs in the first half of 2026, raising a combined £577 million, more than three times the £183 million raised over the same period the previous year. That's still a modest number by the standards of London's pre-2020 heyday, but the direction of travel, after years of consistent decline, is itself meaningfully encouraging to bankers and policymakers who have spent recent years bracing for each new set of quarterly figures.

UK biotech has told a similarly hopeful story in its own corner of the market, with sector-specific venture capital hitting a five-year high in the second quarter of 2026, UK biotech companies raising £498 million in that quarter alone, nearly double the figure from the same period the year before. London continues to account for roughly 60% of all European biotech fundraising, a reminder that Britain's underlying scientific and research strengths, the universities, the talent pool, the research infrastructure, remain genuinely world-class even as the later-stage capital and listing environment around them has struggled to keep pace.

Why the recovery, if it holds, would matter enormously

The stakes here extend well past stock exchange league tables and banker bonuses. Every company that relocates its primary listing, or gets acquired by a foreign buyer specifically because domestic capital wasn't available to fund its next growth stage, takes a meaningful slice of future economic value, tax revenue, and skilled jobs with it. Companies that receive substantial foreign investment are, on average, more likely to eventually exit abroad as well, according to British Business Bank research, meaning today's funding gap doesn't just cost Britain individual companies, it compounds over time into a steady, quiet leakage of the exact high-growth firms the UK economy most needs to retain as it tries to boost productivity and wages over the coming decade.